Market Cap 300.27M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 61,400
Avg Vol 132,070
Day's Range N/A - N/A
Shares Out 147.19M
Stochastic %K 25%
Beta 1.87
Analysts Strong Sell
Price Target $9.50

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
LolaRoss
LolaRoss Oct. 26 at 7:57 AM
$IMMP Success takes time and requires consistent effort. You won't achieve it all at once. Stay focused and keep working step by step @LolaRoss
1 · Reply
IFeelLike
IFeelLike Oct. 24 at 2:14 PM
$IMMP so what's next? November CTOS, again.... the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida. and the first serious cash generator and stock lifter I guess.... For Tacti-004 major update early 2026 CEO: Immutep Chief Executive Officer, Marc Voigt, said, “We are very pleased with the pace of enrolment in our pivotal Phase III trial that we believe has the potential to change the treatment landscape in non-small cell lung cancer, one of the largest indications in oncology with over two million diagnoses annually worldwide. The trial remains on track for key milestones ahead including futility analysis in early 2026.”
0 · Reply
TheIrishCzar
TheIrishCzar Oct. 23 at 8:40 PM
$IMMP interest rate/income rate for borrowed shares at broker changed up to 17.5 today. This has been very very good for the last couple years.
0 · Reply
theinvestaar
theinvestaar Oct. 23 at 8:22 PM
$IMMP AfterHours!
1 · Reply
bylocehi
bylocehi Oct. 23 at 1:31 PM
$IMMP Mr AI says ”While a presentation on eftilagimod alfa (efti) at the San Antonio Breast Cancer Symposium (SABCS) 2025 is possible, it is not confirmed. The manufacturer, Immutep, and investigators have recently presented and published data from its phase II/III AIPAC-003 trial, which studies efti in metastatic breast cancer. Abstracts will be announced October 30” so we wait
1 · Reply
IFeelLike
IFeelLike Oct. 22 at 7:07 PM
$IMMP everybody winning and losing at Beyond Meat? Again 2 billion stocks traded, that's 25 times the stocks available...bizarrrrrr Anyway, still patient for Immp, up to the next conference in november
0 · Reply
Geauxtigers47
Geauxtigers47 Oct. 22 at 2:50 PM
$IMMP you’re welcome for the dip- I added lol
1 · Reply
LAG3boom
LAG3boom Oct. 22 at 2:17 AM
$IMMP Amigos, little disappointed bout upcoming 5000% return with the stock. Hoping 4 10,000% return. What you think?
1 · Reply
theinvestaar
theinvestaar Oct. 22 at 1:02 AM
$IMMP That is HUGE.
2 · Reply
Nico07
Nico07 Oct. 21 at 4:00 PM
$IMMP 3 X better than standard of care! Let’s go Immutep!
0 · Reply
Latest News on IMMP
Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 3 months ago

Immutep Quarterly Activities Report Q4 FY25


Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025, 8:46 AM EDT - 6 months ago

Immutep Limited: Surging On Positive Head And Neck Data


Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Immutep to Participate in Upcoming Investor Conferences


Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 9 months ago

Immutep Quarterly Activities Report Q2 FY25


Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28, 2025, 4:37 PM EST - 9 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod


Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25


Immutep: Navigating The Bumps In The Road

Oct 7, 2024, 9:10 AM EDT - 1 year ago

Immutep: Navigating The Bumps In The Road


Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24


Immutep: Realizing The Expected Catalysts, With More To Come

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come


Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24


Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY24


Immutep: Upcoming Signals For 2024 (Maintain Buy)

Jan 3, 2024, 5:04 PM EST - 1 year ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)


Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial


Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events


Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24


Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive


LolaRoss
LolaRoss Oct. 26 at 7:57 AM
$IMMP Success takes time and requires consistent effort. You won't achieve it all at once. Stay focused and keep working step by step @LolaRoss
1 · Reply
IFeelLike
IFeelLike Oct. 24 at 2:14 PM
$IMMP so what's next? November CTOS, again.... the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida. and the first serious cash generator and stock lifter I guess.... For Tacti-004 major update early 2026 CEO: Immutep Chief Executive Officer, Marc Voigt, said, “We are very pleased with the pace of enrolment in our pivotal Phase III trial that we believe has the potential to change the treatment landscape in non-small cell lung cancer, one of the largest indications in oncology with over two million diagnoses annually worldwide. The trial remains on track for key milestones ahead including futility analysis in early 2026.”
0 · Reply
TheIrishCzar
TheIrishCzar Oct. 23 at 8:40 PM
$IMMP interest rate/income rate for borrowed shares at broker changed up to 17.5 today. This has been very very good for the last couple years.
0 · Reply
theinvestaar
theinvestaar Oct. 23 at 8:22 PM
$IMMP AfterHours!
1 · Reply
bylocehi
bylocehi Oct. 23 at 1:31 PM
$IMMP Mr AI says ”While a presentation on eftilagimod alfa (efti) at the San Antonio Breast Cancer Symposium (SABCS) 2025 is possible, it is not confirmed. The manufacturer, Immutep, and investigators have recently presented and published data from its phase II/III AIPAC-003 trial, which studies efti in metastatic breast cancer. Abstracts will be announced October 30” so we wait
1 · Reply
IFeelLike
IFeelLike Oct. 22 at 7:07 PM
$IMMP everybody winning and losing at Beyond Meat? Again 2 billion stocks traded, that's 25 times the stocks available...bizarrrrrr Anyway, still patient for Immp, up to the next conference in november
0 · Reply
Geauxtigers47
Geauxtigers47 Oct. 22 at 2:50 PM
$IMMP you’re welcome for the dip- I added lol
1 · Reply
LAG3boom
LAG3boom Oct. 22 at 2:17 AM
$IMMP Amigos, little disappointed bout upcoming 5000% return with the stock. Hoping 4 10,000% return. What you think?
1 · Reply
theinvestaar
theinvestaar Oct. 22 at 1:02 AM
$IMMP That is HUGE.
2 · Reply
Nico07
Nico07 Oct. 21 at 4:00 PM
$IMMP 3 X better than standard of care! Let’s go Immutep!
0 · Reply
theinvestaar
theinvestaar Oct. 21 at 1:40 PM
$IMMP this company is worth billions in the future. So many different tumor types so much success to come.
0 · Reply
NOCKNOCK
NOCKNOCK Oct. 21 at 1:35 PM
$IMMP is the one!
0 · Reply
ToRni27
ToRni27 Oct. 21 at 12:18 PM
$IMMP ChatGPT could not find a better cancer stock. First IOVA lung cancer results in very small cohort 55-65% ORR. IOVA got a drug that is very hard to scale and will never supply all patients on the market that need it. Second IBRX still unknown - they even added another drug in phase 3 seems like results were not good. Third SMMT showed worse results in western countries than in china so its unkown if data is accurate.
0 · Reply
ToRni27
ToRni27 Oct. 21 at 4:37 AM
$IMMP Efti is strong with and without chemo. People could choose between chemo free or with chemo but ofc triple combination is more effective. https://www.immutep.com/dw/uploads/2025/08/IMM_Corp_Pres_2025_06_02-1.pdf
0 · Reply
rispi
rispi Oct. 20 at 6:18 PM
0 · Reply
RedemptionwithGod
RedemptionwithGod Oct. 20 at 3:27 PM
0 · Reply
SeatownGreen
SeatownGreen Oct. 20 at 2:47 PM
$IMMP There’s data coming up soon that can help with business development. Let’s make a deal. I don’t know what we’ll see, but turning Sarcoma hot would bring virtually all eyeballs to this trial. This data will apply to eftilagimod alpha in all settings if the mechanism of action is demonstrated.👊
2 · Reply
Tdorsey1776
Tdorsey1776 Oct. 20 at 1:20 PM
$IMMP Shall we assume the stock will pull back AGAIN???
1 · Reply
Gabriel_DS
Gabriel_DS Oct. 20 at 1:18 PM
$IMMP just give us a BO so we can move on after years and years. We know it works and all is great but SP is just crap and will likely stay crap after more good news
1 · Reply
Tdorsey1776
Tdorsey1776 Oct. 20 at 12:53 PM
$IMMP The investigator-initiated Phase II study evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) met the primary endpoint and significantly exceeded the study’s prespecified 35% tumour hyalinization/fibrosis. In the evaluable patient population (N=38), the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis (p<0.001). This impressive outcome, over three times greater than 15% from standard-of-care radiotherapy alone based on historical data, may hold significance in terms of future outcomes as tumour hyalinization/fibrosis serves as an early surrogate endpoint correlated with enhanced overall survival and recurrence-free survival in STS patients.1,2 These promising results were achieved across multiple STS subtypes and the study proved a very good safety profile for the therapy, with only one grade ≥3 toxicity related to immunotherapy.
0 · Reply
GoldenVisions
GoldenVisions Oct. 20 at 12:50 PM
$VRME we have 2 prs thats due, compliance and the crypto strategy pr, it's a no brainer to add more here. This. thing has so much going for itself. $XBP $BGLC $IMMP $AZTR
0 · Reply
BigPennyStockAlerts
BigPennyStockAlerts Oct. 20 at 12:10 PM
$IMMP Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
0 · Reply